New Alzheimer's drug enters human trials: could it slow memory loss?
NCT ID NCT07221344
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study is testing an experimental drug called ARO-MAPT-SC in healthy volunteers and people with early Alzheimer's disease. The goal is to see if the drug is safe and how the body processes it. The drug works by targeting a protein linked to Alzheimer's, with the hope of slowing down memory and thinking problems. The trial involves 112 participants and compares the drug to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGGrafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.